Review



recombinant maltose  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Novus Biologicals recombinant maltose
    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Recombinant Maltose, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant maltose/product/Novus Biologicals
    Average 92 stars, based on 3 article reviews
    recombinant maltose - by Bioz Stars, 2026-06
    92/100 stars

    Images

    1) Product Images from "Identification of Human Transferrin Receptor as an Entry Co-receptor for Parvovirus B19 Infection of Human Erythroid Progenitor Cells"

    Article Title: Identification of Human Transferrin Receptor as an Entry Co-receptor for Parvovirus B19 Infection of Human Erythroid Progenitor Cells

    Journal: bioRxiv

    doi: 10.64898/2026.04.02.715920

    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Figure Legend Snippet: Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).

    Techniques Used: Binding Assay, Inhibition, Control, Incubation, Infection, Concentration Assay, Cell Cycle Assay, Flow Cytometry



    Similar Products

    92
    Novus Biologicals recombinant maltose
    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Recombinant Maltose, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant maltose/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    recombinant maltose - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    92
    Novus Biologicals protein mbp
    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Protein Mbp, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protein mbp/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    protein mbp - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    86
    Anatrace recombinant proteins lauryl maltose neopentyl glycol lmng anatrace cat ng310
    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Recombinant Proteins Lauryl Maltose Neopentyl Glycol Lmng Anatrace Cat Ng310, supplied by Anatrace, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant proteins lauryl maltose neopentyl glycol lmng anatrace cat ng310/product/Anatrace
    Average 86 stars, based on 1 article reviews
    recombinant proteins lauryl maltose neopentyl glycol lmng anatrace cat ng310 - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    86
    Anatrace recombinant proteins lauryl maltose neopentyl glycol lmng anatrace
    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
    Recombinant Proteins Lauryl Maltose Neopentyl Glycol Lmng Anatrace, supplied by Anatrace, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant proteins lauryl maltose neopentyl glycol lmng anatrace/product/Anatrace
    Average 86 stars, based on 1 article reviews
    recombinant proteins lauryl maltose neopentyl glycol lmng anatrace - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    92
    Novus Biologicals bacterial maltose binding protein
    ( a ) Quantification of a monolinked peptide from <t>maltose</t> <t>binding</t> <t>protein</t> (MBP) with or without maltose. Structures of MBP in the open, ligand-free conformation (green, 1mpb.pdb) and the closed, maltose-bound conformation (brown, 1n3w.pdb) are shown on the left. A close-up view of the ‘balancing interface’ is shown on the right. In the closed conformation, the sequence between amino acids 301–312 forms an alpha helix (gray) and K313 forms a salt bridge with E310. The helix and the salt bridge are disrupted in the open conformation (cyan). A crosslinker swapping experiment was performed on the same preparation of MBP; a technical replicate. ( b ) Quantification of monolinked and crosslinked peptides involving K78 and K95 from apo-CaM and CaM with Ca 2+ and CBP. Structures of apo-CaM (left) and CaM + CBP (blue) + Ca 2+ (right) are shown with key lysine residues space filled and magenta. The experiment was performed once.
    Bacterial Maltose Binding Protein, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bacterial maltose binding protein/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    bacterial maltose binding protein - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    92
    Novus Biologicals nbc118538 chemical compound
    ( a ) Quantification of a monolinked peptide from <t>maltose</t> <t>binding</t> <t>protein</t> (MBP) with or without maltose. Structures of MBP in the open, ligand-free conformation (green, 1mpb.pdb) and the closed, maltose-bound conformation (brown, 1n3w.pdb) are shown on the left. A close-up view of the ‘balancing interface’ is shown on the right. In the closed conformation, the sequence between amino acids 301–312 forms an alpha helix (gray) and K313 forms a salt bridge with E310. The helix and the salt bridge are disrupted in the open conformation (cyan). A crosslinker swapping experiment was performed on the same preparation of MBP; a technical replicate. ( b ) Quantification of monolinked and crosslinked peptides involving K78 and K95 from apo-CaM and CaM with Ca 2+ and CBP. Structures of apo-CaM (left) and CaM + CBP (blue) + Ca 2+ (right) are shown with key lysine residues space filled and magenta. The experiment was performed once.
    Nbc118538 Chemical Compound, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nbc118538 chemical compound/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    nbc118538 chemical compound - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    92
    Novus Biologicals recombinant protein bacterial maltose binding protein novus biologicals
    ( a ) Quantification of a monolinked peptide from <t>maltose</t> <t>binding</t> <t>protein</t> (MBP) with or without maltose. Structures of MBP in the open, ligand-free conformation (green, 1mpb.pdb) and the closed, maltose-bound conformation (brown, 1n3w.pdb) are shown on the left. A close-up view of the ‘balancing interface’ is shown on the right. In the closed conformation, the sequence between amino acids 301–312 forms an alpha helix (gray) and K313 forms a salt bridge with E310. The helix and the salt bridge are disrupted in the open conformation (cyan). A crosslinker swapping experiment was performed on the same preparation of MBP; a technical replicate. ( b ) Quantification of monolinked and crosslinked peptides involving K78 and K95 from apo-CaM and CaM with Ca 2+ and CBP. Structures of apo-CaM (left) and CaM + CBP (blue) + Ca 2+ (right) are shown with key lysine residues space filled and magenta. The experiment was performed once.
    Recombinant Protein Bacterial Maltose Binding Protein Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant protein bacterial maltose binding protein novus biologicals/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    recombinant protein bacterial maltose binding protein novus biologicals - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    90
    Novus Biologicals recombinant protein bacterial maltose binding protein

    Recombinant Protein Bacterial Maltose Binding Protein, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant protein bacterial maltose binding protein/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    recombinant protein bacterial maltose binding protein - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).

    Journal: bioRxiv

    Article Title: Identification of Human Transferrin Receptor as an Entry Co-receptor for Parvovirus B19 Infection of Human Erythroid Progenitor Cells

    doi: 10.64898/2026.04.02.715920

    Figure Lengend Snippet: Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).

    Article Snippet: Recombinant Maltose-binding protein (MBP) (#NBC1-18538) was purchased from Novus Biologicals (Centennial, CO).

    Techniques: Binding Assay, Inhibition, Control, Incubation, Infection, Concentration Assay, Cell Cycle Assay, Flow Cytometry

    ( a ) Quantification of a monolinked peptide from maltose binding protein (MBP) with or without maltose. Structures of MBP in the open, ligand-free conformation (green, 1mpb.pdb) and the closed, maltose-bound conformation (brown, 1n3w.pdb) are shown on the left. A close-up view of the ‘balancing interface’ is shown on the right. In the closed conformation, the sequence between amino acids 301–312 forms an alpha helix (gray) and K313 forms a salt bridge with E310. The helix and the salt bridge are disrupted in the open conformation (cyan). A crosslinker swapping experiment was performed on the same preparation of MBP; a technical replicate. ( b ) Quantification of monolinked and crosslinked peptides involving K78 and K95 from apo-CaM and CaM with Ca 2+ and CBP. Structures of apo-CaM (left) and CaM + CBP (blue) + Ca 2+ (right) are shown with key lysine residues space filled and magenta. The experiment was performed once.

    Journal: eLife

    Article Title: Isobaric crosslinking mass spectrometry technology for studying conformational and structural changes in proteins and complexes

    doi: 10.7554/eLife.99809

    Figure Lengend Snippet: ( a ) Quantification of a monolinked peptide from maltose binding protein (MBP) with or without maltose. Structures of MBP in the open, ligand-free conformation (green, 1mpb.pdb) and the closed, maltose-bound conformation (brown, 1n3w.pdb) are shown on the left. A close-up view of the ‘balancing interface’ is shown on the right. In the closed conformation, the sequence between amino acids 301–312 forms an alpha helix (gray) and K313 forms a salt bridge with E310. The helix and the salt bridge are disrupted in the open conformation (cyan). A crosslinker swapping experiment was performed on the same preparation of MBP; a technical replicate. ( b ) Quantification of monolinked and crosslinked peptides involving K78 and K95 from apo-CaM and CaM with Ca 2+ and CBP. Structures of apo-CaM (left) and CaM + CBP (blue) + Ca 2+ (right) are shown with key lysine residues space filled and magenta. The experiment was performed once.

    Article Snippet: Bacterial maltose binding protein was purchased from Novus Biologicals (Littleton, CO).

    Techniques: Binding Assay, Sequencing

    Journal: eLife

    Article Title: Isobaric crosslinking mass spectrometry technology for studying conformational and structural changes in proteins and complexes

    doi: 10.7554/eLife.99809

    Figure Lengend Snippet:

    Article Snippet: Bacterial maltose binding protein was purchased from Novus Biologicals (Littleton, CO).

    Techniques: Recombinant, Binding Assay, Software

    Journal: eLife

    Article Title: Isobaric crosslinking mass spectrometry technology for studying conformational and structural changes in proteins and complexes

    doi: 10.7554/eLife.99809

    Figure Lengend Snippet:

    Article Snippet: Peptide, recombinant protein , Bacterial maltose binding protein , Novus Biologicals , Cat# NBC118538 , .

    Techniques: Recombinant, Binding Assay, Software